Clinical Trial Detail

NCT ID NCT02091531
Title Dual mTOR Inhibitor MLN0128 in Advanced Castration-Resistant Prostate Cancer (CRPC) Patients
Recruitment Completed
Gender male
Phase Phase II
Variant Requirements no
Sponsors Memorial Sloan Kettering Cancer Center
Indications

prostate cancer

Therapies

Sapanisertib

Age Groups: adult

No variant requirements are available.